Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

ABSTRACT Introduction: Camurati-Engelman Disease is a rare genetic sclerosing bone dysplasia with periosteal and endosteal thickening of the cortical of the long bones. It generates pain secondary to the reduction of the medullary canal that is usually controlled with corticosteroids and, in severe cases, with surgical decompression. Case history: We present the case of a woman with a genetic diagnosis of Camurati-Engelman Disease with poor pain control with corticosteroid management and surgical procedures throughout her childhood and early adulthood. In whom optimal pain control was achieved with pain regimen with hydrocodone analgesic management. This is the first case described in the literature for adequate pain control using an opioid drug. Discussion: CE disease is an extremely rare genetic entity with little more than 300 cases reported in the world. It is generated by an alteration in the gene for growth factor-beta 1 (TGF-B1); it has a varied clinical presentation that can begin with bone alterations accompanied by muscle weakness, joint angular alterations, headache, and nerve compressions. It has a differential diagnosis with some genetic entities that may present clinical similarity, but its morphological and radiological characteristics are distinctive. The usual management of bone pain generated by this entity is based on corticosteroids, in addition to losartan or surgical intervention aimed at reducing cortical changes. The intervention with opioid analgesics accompanied by a rehabilitation plan is not a frequent report, this being a case of success due to the refractoriness of the symptoms in a patient with chronic pain, with a positive impact on her functionality and quality of life. Conclusion: It is considered that analgesic management with opioids may be a treatment option in patients with Camurati-Engelman disease refractory to corticosteroid management and surgical interventions.

Saved in:
Bibliographic Details
Main Authors: Arce-Gálvez,L, Grisales-Gafaro,MP, Espinosa-Soto,K, Baena-Álvarez,C
Format: Digital revista
Language:English
Published: Inspira Network Group, S.L 2022
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462022000100009
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1134-80462022000100009
record_format ojs
spelling oai:scielo:S1134-804620220001000092022-10-06Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case reportArce-Gálvez,LGrisales-Gafaro,MPEspinosa-Soto,KBaena-Álvarez,C Opioid pain treatment Camurati-Engelmann progressive diaphyseal dysplasia TGFB-1 ABSTRACT Introduction: Camurati-Engelman Disease is a rare genetic sclerosing bone dysplasia with periosteal and endosteal thickening of the cortical of the long bones. It generates pain secondary to the reduction of the medullary canal that is usually controlled with corticosteroids and, in severe cases, with surgical decompression. Case history: We present the case of a woman with a genetic diagnosis of Camurati-Engelman Disease with poor pain control with corticosteroid management and surgical procedures throughout her childhood and early adulthood. In whom optimal pain control was achieved with pain regimen with hydrocodone analgesic management. This is the first case described in the literature for adequate pain control using an opioid drug. Discussion: CE disease is an extremely rare genetic entity with little more than 300 cases reported in the world. It is generated by an alteration in the gene for growth factor-beta 1 (TGF-B1); it has a varied clinical presentation that can begin with bone alterations accompanied by muscle weakness, joint angular alterations, headache, and nerve compressions. It has a differential diagnosis with some genetic entities that may present clinical similarity, but its morphological and radiological characteristics are distinctive. The usual management of bone pain generated by this entity is based on corticosteroids, in addition to losartan or surgical intervention aimed at reducing cortical changes. The intervention with opioid analgesics accompanied by a rehabilitation plan is not a frequent report, this being a case of success due to the refractoriness of the symptoms in a patient with chronic pain, with a positive impact on her functionality and quality of life. Conclusion: It is considered that analgesic management with opioids may be a treatment option in patients with Camurati-Engelman disease refractory to corticosteroid management and surgical interventions.Inspira Network Group, S.L Revista de la Sociedad Española del Dolor v.29 n.1 20222022-02-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462022000100009en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Arce-Gálvez,L
Grisales-Gafaro,MP
Espinosa-Soto,K
Baena-Álvarez,C
spellingShingle Arce-Gálvez,L
Grisales-Gafaro,MP
Espinosa-Soto,K
Baena-Álvarez,C
Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report
author_facet Arce-Gálvez,L
Grisales-Gafaro,MP
Espinosa-Soto,K
Baena-Álvarez,C
author_sort Arce-Gálvez,L
title Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report
title_short Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report
title_full Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report
title_fullStr Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report
title_full_unstemmed Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report
title_sort bone pain management with opioid medication in a patient with camurati-engelmann disease: a case report
description ABSTRACT Introduction: Camurati-Engelman Disease is a rare genetic sclerosing bone dysplasia with periosteal and endosteal thickening of the cortical of the long bones. It generates pain secondary to the reduction of the medullary canal that is usually controlled with corticosteroids and, in severe cases, with surgical decompression. Case history: We present the case of a woman with a genetic diagnosis of Camurati-Engelman Disease with poor pain control with corticosteroid management and surgical procedures throughout her childhood and early adulthood. In whom optimal pain control was achieved with pain regimen with hydrocodone analgesic management. This is the first case described in the literature for adequate pain control using an opioid drug. Discussion: CE disease is an extremely rare genetic entity with little more than 300 cases reported in the world. It is generated by an alteration in the gene for growth factor-beta 1 (TGF-B1); it has a varied clinical presentation that can begin with bone alterations accompanied by muscle weakness, joint angular alterations, headache, and nerve compressions. It has a differential diagnosis with some genetic entities that may present clinical similarity, but its morphological and radiological characteristics are distinctive. The usual management of bone pain generated by this entity is based on corticosteroids, in addition to losartan or surgical intervention aimed at reducing cortical changes. The intervention with opioid analgesics accompanied by a rehabilitation plan is not a frequent report, this being a case of success due to the refractoriness of the symptoms in a patient with chronic pain, with a positive impact on her functionality and quality of life. Conclusion: It is considered that analgesic management with opioids may be a treatment option in patients with Camurati-Engelman disease refractory to corticosteroid management and surgical interventions.
publisher Inspira Network Group, S.L
publishDate 2022
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462022000100009
work_keys_str_mv AT arcegalvezl bonepainmanagementwithopioidmedicationinapatientwithcamuratiengelmanndiseaseacasereport
AT grisalesgafaromp bonepainmanagementwithopioidmedicationinapatientwithcamuratiengelmanndiseaseacasereport
AT espinosasotok bonepainmanagementwithopioidmedicationinapatientwithcamuratiengelmanndiseaseacasereport
AT baenaalvarezc bonepainmanagementwithopioidmedicationinapatientwithcamuratiengelmanndiseaseacasereport
_version_ 1755939579372765184